Halloran Town Hall: How the Inflation Reduction Act is Impacting Product Development Programs

The Inflation Reduction Act (IRA) contains $500 billion in new spending and tax breaks aimed at reducing healthcare costs, boost clean energy, and increase tax revenues. Since signed into law on August 16, 2022, the life science industry continues to mull its impacts to the healthcare ecosystem.

While the IRA seeks to lower prescription drug costs by allowing Medicare to negotiate prices with product development companies, place an inflation cap on drug prices, and lower out-of-pocket expenses for Medicare recipients, product developers are already noticing significant impacts and juggling tradeoffs. Conversely, many developers remain unaware that the IRA may impact their programs.

Please join us for a virtual Town Hall – How the Inflation Reduction Act is Impacting Product Development Programs – led by Katie McCarthy, Halloran’s Chief Innovation Officer, in collaboration with industry colleagues:

• Kendalle Burlin O’Connell, President & CEO, MassBio
• Tamar Thompson, Head of Global Corporate Affairs & DEI Lead, Alexion Pharmaceuticals
• Neil Di Spirito, Partner, Brown Rudnick
• John Stanford, Managing Partner, Prism Group

Prepare to learn:

• IRA basics and fundamentals
• Overview of life science industry response
• Examples of how the IRA is impacting product development programs
• Suggestions and strategic considerations to navigate IRA implications

As we navigate this new legislation together, now is the time to collectively share examples, suggestions, and considerations for success.

Upon registration, you will receive a calendar invite with Zoom info.

Please feel free to distribute this event and any questions, contact townhall@hallorancg.com.